论文部分内容阅读
目的观察紫杉醇、卡铂联合治疗晚期非小细胞肺癌的临床疗效及毒副反应。方法 45例晚期非小细胞肺癌患者应用紫杉醇、卡铂联合治疗。治疗2个周期后,观察临床疗效及毒副反应。结果 45例患者均完成3个以上周期治疗,临床总有效率为48.9%(22/45);患者毒副反应均较轻微,经对症处置后未影响下一周期治疗。结论紫杉醇、卡铂联合化疗方案治疗晚期非小细胞肺癌临床疗效较好,毒副反应轻微,值得临床进一步研究应用。
Objective To observe the clinical efficacy and side effects of paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer. Methods Forty-five patients with advanced non-small cell lung cancer were treated with paclitaxel and carboplatin. After 2 cycles of treatment, clinical efficacy and side effects were observed. Results All 45 patients completed more than 3 cycles of treatment, with a total clinical effective rate of 48.9% (22/45). Toxic side effects were mild in patients and did not affect the next cycle after symptomatic treatment. Conclusion paclitaxel and carboplatin combined chemotherapy in the treatment of advanced non-small cell lung cancer has good clinical efficacy and mild side effects, which deserves further clinical application.